Summary
Public procurers in ProEmpower aim to procure a disease self-management solution to help meet the imminent threat of a diabetes epidemic. ProEmpower will make person-centred care reality - giving the patient the steering wheel - for optimal health outcomes. Very significant synergies will be reaped by supporting all 10 action areas of diabetes management in an integrated ICT solution. Early detection, personal decision support, self management and peer support are to be delivered from a platform with full interoperable and secure access to the necessary devices and health records. ProEmpower will apply the internationally acclaimed Chronic Care Model to specify support needs for type 2 diabetes at all stages. Self-management and treatment will be supported by personalised guidelines and making the best use of clinical data. In this way a quality culture in healthcare will be fostered and learning healthcare systems made reality.
Suppliers will be rigorously evaluated after each of the four procurement phases, comprising (I) an open market consultation supported by the European eHealth Competition, (II) specification of architecture and system aligned to requirements of patients, peers and providers, (III) prototype development and testing with end-users and (IV) effectiveness proven in a trial with 200 patients and 40 professionals.
Fully rolled out in the four countries, enabled by procurers with the authority and capacity in their countries and regions, ProEmpower will serve 12 million diabetes patients.
Reductions in diabetes-related death, amputation, blindness and renal failure promise cost relief of € 53 billion over 7 years in the four countries. Suppliers can expect a turnover of € 5 billion a year. Proven ability to cover the four different health systems promises ProEmpower suppliers easy entry into other EU markets and beyond, a very strong contribution to overcoming fragmentation of demand and fostering the global market.
Suppliers will be rigorously evaluated after each of the four procurement phases, comprising (I) an open market consultation supported by the European eHealth Competition, (II) specification of architecture and system aligned to requirements of patients, peers and providers, (III) prototype development and testing with end-users and (IV) effectiveness proven in a trial with 200 patients and 40 professionals.
Fully rolled out in the four countries, enabled by procurers with the authority and capacity in their countries and regions, ProEmpower will serve 12 million diabetes patients.
Reductions in diabetes-related death, amputation, blindness and renal failure promise cost relief of € 53 billion over 7 years in the four countries. Suppliers can expect a turnover of € 5 billion a year. Proven ability to cover the four different health systems promises ProEmpower suppliers easy entry into other EU markets and beyond, a very strong contribution to overcoming fragmentation of demand and fostering the global market.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/727409 |
| Start date: | 01-10-2016 |
| End date: | 30-09-2020 |
| Total budget - Public funding: | 4 280 752,50 Euro - 3 852 677,00 Euro |
Cordis data
Original description
Public procurers in ProEmpower aim to procure a disease self-management solution to help meet the imminent threat of a diabetes epidemic. ProEmpower will make person-centred care reality - giving the patient the steering wheel - for optimal health outcomes. Very significant synergies will be reaped by supporting all 10 action areas of diabetes management in an integrated ICT solution. Early detection, personal decision support, self management and peer support are to be delivered from a platform with full interoperable and secure access to the necessary devices and health records. ProEmpower will apply the internationally acclaimed Chronic Care Model to specify support needs for type 2 diabetes at all stages. Self-management and treatment will be supported by personalised guidelines and making the best use of clinical data. In this way a quality culture in healthcare will be fostered and learning healthcare systems made reality.Suppliers will be rigorously evaluated after each of the four procurement phases, comprising (I) an open market consultation supported by the European eHealth Competition, (II) specification of architecture and system aligned to requirements of patients, peers and providers, (III) prototype development and testing with end-users and (IV) effectiveness proven in a trial with 200 patients and 40 professionals.
Fully rolled out in the four countries, enabled by procurers with the authority and capacity in their countries and regions, ProEmpower will serve 12 million diabetes patients.
Reductions in diabetes-related death, amputation, blindness and renal failure promise cost relief of € 53 billion over 7 years in the four countries. Suppliers can expect a turnover of € 5 billion a year. Proven ability to cover the four different health systems promises ProEmpower suppliers easy entry into other EU markets and beyond, a very strong contribution to overcoming fragmentation of demand and fostering the global market.
Status
CLOSEDCall topic
SC1-PM-12-2016Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
Organisations
-
| Turkiye Cumhuriyeti Saglik Bakanligi (Coördinator)
-
| AZIENDA OSPEDALIERA UNIVERSITARIA FEDERICO II
-
| CENTER FOR PROTECTION OF THE RIGHTSIN THE HEALTHCARE SDRUZHENIE
-
| EMPIRICA GESELLSCHAFT FUR KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG MBH
-
| FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA
-
| IRMANDADE DA SANTA CASA DA MISERICORDIA DA AMADORA IPSS
-
| SERVICIO MURCIANO DE SALUD
-
| SOCIETA' REGIONALE PER LA SANITA' SPA
-
| SPMS - SERVICOS PARTILHADOS DO MINISTERIO DA SAUDE EPE
-
| TICBIOMED TECNOLOGIAS DE LA INFORMACION PARA LA SALUD EN LA REGION DE MURCIA ASOCIACION
-
| UNIVERSITA DEGLI STUDI DI SALERNO